Library Open Repository

ABT-874, a fully human monoclonal anti-IL-12/IL-23 antibody for the potential treatment of autoimmune diseases.

Downloads

Downloads per month over past year

Ding, C and Xu, J and Li, J (2008) ABT-874, a fully human monoclonal anti-IL-12/IL-23 antibody for the potential treatment of autoimmune diseases. Current Opinion in Investigational Drugs, 9 (5). pp. 515-522. ISSN 1472-4472

[img]
Preview
PDF
ABT-874.pdf | Download (370kB)
Available under University of Tasmania Standard License.

Abstract

ABT-874, a fully human mAb that blocks the binding of IL-12 and IL-23 to their shared IL-12 receptor beta1, is currently being developed by Abbott Laboratories for the potential treatment of Crohn's disease and psoriasis. The compound is currently in phase III clinical trials for psoriasis and phase II trials for Crohn's disease. ABT-87 was previously being developed for the potential treatment of multiple sclerosis; however, by May 2007, development for this indication was discontinued.

Item Type: Article
Journal or Publication Title: Current Opinion in Investigational Drugs
Page Range: pp. 515-522
ISSN: 1472-4472
Additional Information: Changhai Ding
Date Deposited: 11 Jun 2008 03:56
Last Modified: 18 Nov 2014 03:41
URI: http://eprints.utas.edu.au/id/eprint/6553
Item Statistics: View statistics for this item

Repository Staff Only (login required)

Item Control Page Item Control Page